As per the recently published report by MarketsandMarkets™, The report “HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region – Global Forecast to 2028″, is projected to reach USD 2.1 billion by 2028 from an estimated value of USD 1.4 billion in 2022, at a CAGR of 6.5% during the forecast period.
Download PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877
Browse
- 180 Market Data Tables
- 37 Figures
- 223 Pages and in-depth TOC on “ HLA Typing Market – Global Forecast to 2028”
Some of the prominent key players are:
- Bio-Rad Laboratories, Inc. (US),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- QIAGEN N.V. (Netherlands),
- Thermo Fisher Scientific Inc. (US),
- bioMérieux S.A. (France) and many more……
Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the HLA Typing Market.
Request Sample Pages: –https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877
- Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022.
- Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion.
- Based on application, the diagnostic applications market is segmented into donor-recipient match, Cancer Diagnosis and prevention, Infectious and non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecast period.
- Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of the HLA Typing Market.
Recent Developments:
- In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System
- In August 2022 Roche developed a new digital Light cycler system that helps determine a patient’s cancer.
- In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.
